RECURRENT ORAL MUCOSITIS IN METASTATIC MELANOMA PATIENT TREATED WITH CHECKPOINT INHIBITOR, PEMBROLIZUMAB: CASE REPORT AND LITERATURE REVIEW

J. Dimitrijevic¹, S. Bosnjak¹, S. Matkovic², N. Babovic², S. Susnjar¹.

¹*Institute of Oncology and Radiology of Serbia, Oncology intensive care unit and supportive oncology mobile team, Belgrade, Serbia.*
²*Institute of Oncology and Radiology of Serbia, Department for soft tissue sarcoma- melanoma and urologic malignancies, Belgrade, Serbia*

Introductions

Pembrolizumab is up to date strategy against various types of cancer including melanoma. It has an unique type of adverse events (AE's) described as immune-related AE's (irAE's) connected with excessive immune system activation. Immune-related oral mucositis (irOM) with pembrolizumab is rarely described in literature.

Objectives

To report a case of a 57-year-old patient with metastatic melanoma treated with pembrolizumab who developed a recurrent irOM

Methods

Assessment and treatment of irOM was performed according to the MASCC/ESMO guidelines for oral mucositis and ESMO guidelines for management of immunotherapy toxicity. IrAE's severity was assessed by CTCAE and WHO criteria. A retrospective literature search of published data was conducted.

Results

Patient developed grade 2 irOM after the first cycle and grade 4 irOM after the second cycle of pembrolizumab (Figure 1). OM was judged as an irAE's because of its recurrent nature and after other causes were excluded. IrOM of grade 4 was rather unresponsive to therapy: after one month it was downgraded to grade 3. Additional immunosuppressive agents are not accessible in Serbia for irAE's (off-label indication). Anti-PD1 antibody induced oral mucositis is reported, but rarely for pembrolizumab. Rapoport et al. 2017 described immune-related oral manifestations in the form of lichenoid reactions, but not OM.

Fig.1 Grade 4 irOM after the second cycle of pembrolizumab

TREATMENT

- ❖ Methyprednisolone 1mg/kg i.v
- ❖ Dexamethasone oral rinses
- ❖ Local analgesia (benzidine oral solution and morphine oral solution)
- ❖ Systemic analgesia (fentanyl TD patch and i.v morphine)
- ❖ Parenteral antibiotic (cefazolin i.v)
- ❖ Parenteral nutrition

Additional immunosuppressives not accessible

Conclusions

Immune-related oral mucositis is an uncommon irAE of pembrolizumab. The best approach to the management of irOM is yet to be defined.

Any questions??
drjelenadimitrijevic@gmail.com